Author/Authors :
Ahmadi Nejad, N Department of Radiology - Medical Imaging Center - Imam Khomeini Hospital - Tehran University of Medical Sciences, Tehran , Guity, M Department of Radiology - Medical Imaging Center - Imam Khomeini Hospital - Tehran University of Medical Sciences, Tehran , Farahani, M Imam Khomeini Hospital - Tehran University of Medical Sciences, Tehran , Farzane, S Imam Khomeini Hospital - Tehran University of Medical Sciences, Tehran , Shakiba, M Imam Khomeini Hospital - Tehran University of Medical Sciences, Tehran , Jalali, A. H Imam Khomeini Hospital - Tehran University of Medical Sciences, Tehran
Abstract :
Background/Objectives: To determine the effects of estrogen and estrogen plus progesterone
on mammographic density in postmenopausal women.
Patients and Methods: In a descriptive cohort study, ba seline and 12-month mammograms
were obtained from 97 healthy postmenopausal women, aged 45-55 years. Estrogen or combined
estrogen and progesterone replacement ther apies were used for them. After one year,
we classified breast density in the first and second mammograms according to Breast Imaging
Reporting and Data System (BIRADS) as patterns 1 (mostly fatty) through 4 (mostly dense
tissue).
Results: None of our cases had a decrease in density, while 35.1% showed an increased density.
The results showed that an increase in mammographic density had no significant association
with the type of prescribed hormone (P=0.77).
In cases with no change in density, the parity was 3.51.86; while in the group with one-level
rise, it was 4.241.84; and 5.21. 92 in the two-level rise group.
Statistical analysis showed that changes in density had significant association with parity in
our cases (P=0.015).
Conclusion: HRT was associated with increases in mammographic density, suggesting that
increasing mammographic density may be a marker of elevated breast cancer risk in postmenopausal
women who use postmenopausal hormone replacement therapies. However, the
link between changes in breast density resulting from hormone use and the change in breast
cancer risk remains uncertain.